Ekr Therapeutics is classified as operating in the Medical Laboratories industry, NAICS Code 621511.
Trademark Applications
Trademark applications show the products and services that Ekr Therapeutics is developing and marketing.
Ekr Therapeutics doesn't have any recent trademark applications, indicating Ekr Therapeutics is focusing on
its existing business rather than expanding into new products and markets.
Trademarks may include brand names, product names, logos and slogans.
Trademark
Date
RETAFLO Enzymes for medical purposes, thrombolytic enzymes for catheter clearance
10/29/2010
RENSTINCT Pharmaceutical preparations for the treatment of cardiac diseases and renal disorders
05/04/2006
RETAVASE cardiovascular agent, namely, a recombinant plasminogen activator compound, for use in the management of acute myocardial infarction
07/15/1997
See all trademarks and details in the Full Report.
Market Share of Ekr Therapeutics's Largest Competitors
A competitive analysis shows these companies are in the same general field as Ekr Therapeutics, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Ekr Therapeutics.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
Future Competition: Ekr Therapeutics's Fastest Growing Competitors
These companies are in the same general field as Ekr Therapeutics and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.